Caricamento...
Clinical Management of Adverse Events Associated with Lorlatinib
Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second‐generation ALK TKIs. The safety profile of lorlatini...
Salvato in:
| Pubblicato in: | Oncologist |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693708/ https://ncbi.nlm.nih.gov/pubmed/30890623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0380 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|